Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.

Rischin D, Hughes BGM, Basset-Séguin N, Schadendorf D, Bowyer S, Trabelsi Messai S, Meier F, Eigentler TK, Casado Echarren V, Stein B, Beylot-Barry M, Dalac S, Dréno B, Migden MR, Hausschild A, Schmults CD, Lim AM, Yoo SY, Paccaly AJ, Papachristos A, Nguyen JH, Okoye E, Seebach F, Booth J, Lowy I, Fury MG, Guminski A

J Immunother Cancer. 2024 03 11;12(3):

The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.

Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, Boespflug A,

Ann Dermatol Venereol. 2024 02 6;151(1):103243

Duration of treatment with cemiplimab in advanced cutaneous squamous cell carcinoma in complete response : Real-life study.

Khelef K, Maubec E, Jeudy G, Bonniaud B, Pham-Ledard A, Herms F, Aubin F, Beneton N, Dinulescu M, Jannic A, Duval-Modeste A, Archier E, Berthin C, Grange F, Arnault J, Heidelberger V, Moncourier M, Mansard S, Brunet-Possenti F, Triller R, Pracht M, Dumas M, Lauche O, Mortier L, Bedane C, Dalac Rat S

J Eur Acad Dermatol Venereol. 2023 08 18;:

Hyperprogression in advanced melanoma is not restricted to immunotherapy.

Fournier M, Mortier L, Dereure O, Dalac S, Oriano B, Dalle S, Lebbé C

Eur J Cancer. 2023 08 11;193:113289

Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome. A multicentre, retrospective, real-world French study.

Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, Dobos G, Pham-Ledard A, Ram-Wolff C, D'Incan M, Grange F, Braniste V, Bagot M

J Eur Acad Dermatol Venereol. 2023 04 27;:

Endotracheal tube biofilm in critically ill patients during the COVID-19 pandemic : description of an underestimated microbiological compartment.

Maldiney T, Pineau V, Neuwirth C, Ouzen L, Eberl I, Jeudy G, Dalac S, Piroth L, Blot M, Sautour M, Dalle F, Abdulmalak C, Ter Schiphorst R, Pugliesi PS, Poussant T, Ogier-Desserrey A, Fournel I, de Giraud d'Agay M, Jacquier M, Labruyère M, Aptel F, Roudaut JB, Vieille T, Andreu P, Prin S, Charles PE, Hamet M, Quenot JP

Sci Rep. 2022 12 27;12(1):22389

Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort.

Rousset P, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Brunet-Possenti F, De Quatrebarbes J, Grob JJ, Saiag P, Maubec E, Stoebner PE, Granel-Brocard F, Arnault JP, Allayous C, Oriano B, Lebbe C, Montaudié H

J Am Acad Dermatol. 2022 12 19;:

Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France.

Kandel M, Bardet A, Dalle S, Allayous C, Mortier L, Guillot B, Dutriaux C, Leccia MT, Dalac S, Montaudie H, Saiag P, Legoupil D, Brunet-Possenti F, Arnault JP, Quatrebarbes J, Beylot-Barry M, Maubec E, Lesimple T, Aubin F, Grob JJ, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I

Curr Oncol. 2022 11 27;29(12):9255-9270

A case of ichtyosiform and morpheaform sarcoidosis.

Pons S, Dalac S, Aubriot-Lorton MH, Vervandier A, Landais C, Collet E

Ann Dermatol Venereol. 2022 11 22;:

Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database.

L'Orphelin JM, Le Naour S, Dalle S, Varey E, Dupuy A, Montaudie H, Lesage C, Mortier L, Leccia MT, Celerier P, Skowron F, Meyer N, Maubec E, Amini-Adle M, Dalac-Rat S, Dutriaux C, Khammari A, Dompmartin A, Dreno B,

Eur J Dermatol. 2022 11 1;32(6):691-697

Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort.

Girod M, Dalle S, Mortier L, Dalac S, Leccia MT, Dutriaux C, Montaudié H, de Quatrebarbes J, Lesimple T, Brunet-Possenti F, Saiag P, Maubec E, Legoupil D, Stoebner PE, Arnault JP, Lefevre W, Lebbe C, Dereure O

JCO Precis Oncol. 2022 11;6:e2200075

Cutaneous vasculitis associated with Mycosis Fungoides.

Nardin C, Lesage C, Goubeau E, Aubriot-Lorton MH, Lacheretz-Szablewski V, Ortonne N, Saizonou I, Aubin F, Dereure O, Dalac-Rat S

J Eur Acad Dermatol Venereol. 2022 10 12;:

An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.

Dutriaux C, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Saiag P

Eur J Cancer. 2022 09 25;175:254-262

Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.

Plaçais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, Montaudié H, Arnault JP, De Quatrebarbes J, Saiag P, Brunet-Possenti F, Lesimple T, Maubec E, Aubin F, Granel-Brocard F, Grob JJ, Stoebner PE, Allayous C, Oriano B, Dutriaux C, Mortier L, Lebbe C

Ann Rheum Dis. 2022 07 4;:

Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database.

Bassompierre A, Dalac S, Dreno B, Neidhardt EM, Maubec E, Capelle C, Andre F, Behal H, Dziwniel V, Bens G, Leccia MT, Meyer N, Granel-Brocard F, Beylot-Barry M, Dereure O, Basset-Seguin N, Mortier L

ESMO Open. 2021 Oct 21;6(6):100284

Characterization of patients with advanced basal cell carcinoma progressing while receiving Hedgehog pathway inhibitors.

Monnet P, Herms F, Djermane M, Dalac S, Dereure O, Dréno B, Beylot-Barry M, Mortier L, Basset-Seguin N

Br J Dermatol. 2021 Oct 12;:

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.

Hober C, Fredeau L, Pham-Ledard A, Boubaya M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A, Meyer N, Duval-Modeste AB, Cesaire L, Neidhardt ÈM, Archier É, Dréno B, Lesage C, Berthin C, Kramkimel N, Grange F, de Quatrebarbes J, Stoebner PE, Poulalhon N, Arnault JP, Abed S, Bonniaud B, Darras S, Heidelberger V, Devaux S, Moncourier M, Misery L, Mansard S, Etienne M, Brunet-Possenti F, Jacobzone C, Lesbazeilles R, Skowron F, Sanchez J, Catala S, Samimi M, Tazi Y, Spaeth D, Gaudy-Marqueste C, Collard O, Triller R, Pracht M, Dumas M, Peuvrel L, Combe P, Lauche O, Guillet P, Reguerre Y, Kupfer-Bessaguet I, Solub D, Schoeffler A, Bedane C, Quéreux G, Dalac S, Mortier L, Maubec È

Cancers (Basel). 2021 Jul 15;13(14):

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabraf

Saiag P, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C

Eur J Cancer. 2021 Jul 6;154:57-65

Late-onset adverse events under anti-PD1 therapy in melanoma patients: an observational study from MELBASE, a nationwide prospective cohort.

Carlet C, Dalle S, Leccia MT, Mortier L, Dalac-Rat S, Dutriaux C, Legoupil D, Montaudié H, Dereure O, De Quatrebarbes J, Granel-Brocard F, Le-Bouar M, Charles J, Brunet-Possenti F, Dreno B, Lefevre W, Allayous C, Lebbe C, Nardin C

J Am Acad Dermatol. 2021 Jun 18;:

Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma.

Becquart O, Oriano B, Dalle S, Mortier L, Leccia MT, Dutriaux C, Dalac S, Montaudié H, De Quatrebarbes J, Brunet-Possenti F, Saiag P, Lesimple T, Beylot-Barry M, Aubin F, Stoebner PE, Arnault JP, Dreno B, Porcher R, Lebbe C, Guillot B

Cancers (Basel). 2021 Jun 18;13(12):

Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database.

Casarotto E, Chandwani S, Mortier L, Dereure O, Dutriaux C, Dalac S, Scherrer E, Lévy-Bachelot L, Verdoni L, Farge G, Allayous C, Oriano B, Dalle S, Lebbé C

Immunotherapy. 2021 Jun 2;:

Effectiveness and Safety of Nivolumab in Patients with Advanced Melanoma: A Multicenter, Observational Study.

Monestier S, Dalle S, Mortier L, Dutriaux C, Dalac-Rat S, Meyer N, Leccia MT, Mansard S, Montaudié H, Saiag P, Combemale P, Guillot B, Skowron F, Modeste AD, Bénéton N, Hainaut E, Robert C, Arnault JP, Le Corre Y, Jouary T, Ameur N, Varey E, Khammari A, Dréno B,

Int J Cancer. 2021 Jan 11;:

Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data.

Di Filippo Y, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Saiag P, Brunet-Possenti F, Arnnault JP, Maubec E, Granel-Brocard F, De Quatrebarbes J, Aubin F, Lesimple T, Beylot-Barry M, Stoebner PE, Dupuy A, Stephan A, Grob JJ, Lefevre W, Oriano B, Allayous C, Lebbé C, Montaudié H

Ann Oncol. 2020 Dec 29;:

Epidemiological changes in cutaneous lymphomas: an analysis of 8,593 patients from the French Cutaneous Lymphoma Registry.

Dobos G, de Masson A, Ram-Wolff C, Beylot-Barry M, Pham-Ledard A, Ortonne N, Ingen-Housz-Oro S, Battistella M, D Incan M, Rouanet J, Franck F, Vignon-Pennamen MD, Franck N, Carlotti A, Boulinguez S, Lamant L, Petrella T, Dalac S, Joly P, Courville P, Rivet J, Dereure O, Amatore F, Taix S, Grange F, Durlach A, Quéreux G, Josselin N, Moulonguet I, Mortier L, Dubois R, Maubec E, Laroche L, Michel L, Templier I, Barete S, Nardin C, Augereau O, Vergier B, Bagot M

Br J Dermatol. 2020 Oct 31;:

A multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans.

Delyon J, Porcher R, Battistella M, Meyer N, Adamski H, Bertucci F, Guillot B, Jouary T, Leccia MT, Dalac S, Mortier L, Ghrieb Z, Meda LD, Vicaut E, Pedeutour F, Mourah S, Lebbe C

J. Invest. Dermatol.. 2020 Sep 18;:

BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.

Frazao A, Rethacker L, Jeudy G, Colombo M, Pasmant E, Avril MF, Toubert A, Moins-Teisserenc H, Roelens M, Dalac S, Maubec E, Caignard A

J Immunother Cancer. 2020 Sep;8(2):

Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database.

Dalle S, Varey E, Nguyen JM, Dupuy A, Montaudie H, Lesage C, Mortier L, Leccia MT, Skowron F, Celerier P, Meyer N, Dutriaux C, Dalac-Rat S, Khammari A, Lebbe C, Dréno B

Eur J Dermatol. 2020 Aug 19;:

Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.

Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguin N, Deschamps L, Grob JJ, Dréno B, Scheer-Senyarich I, Bloch-Queyrat C, Leccia MT, Stefan A, Saiag P, Grange F, Meyer N, de Quatrebarbes J, Dinulescu M, Legoupil D, Machet L, Dereure O, Zehou O, Montaudié H, Wierzbicka-Hainaut E, Le Corre Y, Mansard S, Guégan S, Arnault JP, Dalac S, Aubin F, Alloux C, Lopez I, Cherbal S, Tibi A, Lévy V,

J. Clin. Oncol.. 2020 Jul 30;:JCO1903357

COVID-19 and skin cancer management: French nation-wide questionnaire survey from real-life practice.

Nardin C, Puzenat E, Dalac S, Maubec E, Aubin F,

J Dermatolog Treat. 2020 Jul 29;:1-6

Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology department.

de Grégori J, Pistre P, Boutet M, Porcher L, Devaux M, Pernot C, L Chrétien M, Rossi C, Manfredi S, Dalac S, Gueneau P, Boulin M

J Oncol Pharm Pract. 2020 Apr 16;:1078155220915763

[Stage III melanoma: Sentinel node biopsy, completion lymph node dissection and prospects of adjuvant therapy. A French national survey on current and envisaged practices].

Orion C, Dinulescu M, Dalac-Rat S, Giacchero D, Jouary T, Lebbé C, Leccia MT, Maubec E, Meyer N, Mortier L, Dupuy A,

Ann Dermatol Venereol. 2020 Jan;147(1):9-17

Quality-of-life assessment in French patients with metastatic melanoma in real life.

Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I

Cancer. 2019 Oct 22;:

Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.

Herms F, Lambert J, Grob JJ, Haudebourg L, Bagot M, Dalac S, Dutriaux C, Guillot B, Jeudy G, Mateus C, Monestier S, Mortier L, Poulalhon N, Prey S, Robert C, Vabres P, Lebbe C, Meyer N, Basset-Seguin N

J. Clin. Oncol.. 2019 Oct 14;:JCO1800794

[Creation, implementation and objectives of CARADERM, a national network for rare skin carcinomas - Adnexal neoplasm part].

Seris A, Battistella M, Beylot-Barry M, Dalle S, Mortier L, Lebbé C, Blom A, Neidhart-Berard EM, Kramkimel N, Dupuy A, Zehou O, Dalac S, Jullie ML, Cribier B, Jouary T, ,

Ann Dermatol Venereol. 2019 Sep 30;:

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.

Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, Lebbé C,

JAMA Dermatol. 2019 May 1;:

Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.

Tétu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dreno B, Mohamed S, Ballon A, Porcher R, Lebbe C

Eur. J. Cancer. 2019 May;112:38-46

Evaluation of TLC-NOSF dressing with poly-absorbent fibres in exuding leg ulcers: two multicentric, single-arm, prospective, open-label clinical trials.

Sigal ML, Addala A, Maillard H, Chahim M, Sala F, Blaise S, Dalac S, Meaume S, Bohbot S, Tumba C, Tacca O

J Wound Care. 2019 Mar 3;28(3):164-175

Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.

Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I

Eur. J. Cancer. 2018 Oct 29;105:33-40

Assessment of quality of life in patients with metastatic melanoma in real clinical practice in France.

Kandel M, Allayous C, Dalle S, Mortier L, Dalac Rat S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Brunet-Possenti F, Dreno B, Ballon A, Bardet A, Michiels S, Lebbe C, Borget I

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii460

Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas.

Menguy S, Frison E, Prochazkova-Carlotti M, Dalle S, Dereure O, Boulinguez S, Dalac S, Machet L, Ram-Wolff C, Verneuil L, Gros A, Vergier B, Beylot-Barry M, Merlio JP, Pham-Ledard A

Mod. Pathol.. 2018 Mar 26;:

STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.

Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C,

J. Invest. Dermatol.. 2017 Aug;:

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma.

Kientz C, Joly MO, Faivre L, Clemenson A, Dalac S, Lepage C, Chapusot C, Jacquot C, Schiappa R, Lebrun M

Hered Cancer Clin Pract. 2017 ;15:6

French updated recommendations in Stage I to III melanoma treatment and management.

Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardiere A, Hindie E, Jouary T, Lassau N, Mirabel X, Piperno Neumann S, De Raucourt S, Vanwijck R

J Eur Acad Dermatol Venereol. 2017 Jan;:

[Update to the recommendations for management of melanoma stages I to III].

Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardière A, Hindie E, Jouary T, Lassau N, Mirabel X, Piperno Neumann S, De Raucourt S, Vanwijck R

Ann Dermatol Venereol. 2016 Oct;143(10):629-652

A Typical Vascular and Pigmentary Dermoscopic Pattern of Capillary Malformations in Capillary Malformation-Arteriovenous Malformation Syndrome: Report of Four Cases.

Gandon C, Bonniaud B, Collet E, Dalac S, Jeudy G, Vabres P

Pediatr Dermatol. 2016 Sep;33(5):e337-41

Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial.

Dalac S, Sigal L, Addala A, Chahim M, Faivre-Carrere C, Lemdjadi Z, Bohbot S

J Wound Care. 2016 Sep;25(9):531-8

[Guidelines for stage I to III melanoma].

Guillot B, Dalac S, Denis M, Dupuy A, Emile JF, De La Fouchardiere A, Hindie E, Jouary T, Lassau N, Mirabel X, Piperno Neumann S, De Raucourt S, Vanwijck R

Bull Cancer. 2016 Sep;103(9):743-52

Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis.

Cordel N, Tressières B, D'Incan M, Machet L, Grange F, Estève É, Dalac S, Ingen-Housz-Oro S, Bagot M, Beylot-Barry M, Joly P,

Oncologist. 2016 Jan;21(1):76-83

Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides A prospective multicenter trial of the Cutaneous Lymphoma French Study Group.

Hurabielle C, Ingen-Housz-Oro S, Ortonne N, Cornillet-Lefebvre P, Merah A, D'Incan M, Joly P, Franck N, Esteve E, Maubec E, Grange F, Machet L, Laroche L, Barete S, Dalac S, Mortier L, Michel C, Quereux G, Saiag P, Ram-Wolff C, Lenormand B, Wechsler J, Bastuji-Garin S, Bagot M, Delfau-Larue MH

Br J Dermatol. 2015 Jul 6

Sentinel Node Status and Immunosuppression: Recurrence Factors in Localized Merkel Cell Carcinoma.

Jouary T, Kubica E, Dalle S, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Dompmartin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Ezzedine K, Mateus C

Acta Derm Venereol. 2015 Mar 18

Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.

Jeudy G, Dalac-Rat S, Bonniaud B, Hervieu A, Petrella T, Collet E, Vabres P

Br. J. Dermatol.. 2015 ;172(5):1454-5

Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients.

Julia F, Dalle S, Duru G, Balme B, Vergier B, Ortonne N, Vignon-Pennamen MD, Costes-Martineau V, Lamant L, Dalac S, Delattre C, Dechelotte P, Courville P, Carlotti A, De Muret A, Fraitag S, Levy A, Mitchell A, Petrella T

Am J Surg Pathol. 2014 May;38(5):673-80

Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France.

Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, Maubec E, D'Incan M, Ram-Wolff C, Dalac S, Templier I, Esteve E, Quereux G, Machet L, Leduc M, Dereure O, Laroche L, Saiag P, Vergier B, Beylot-Barry M

JAMA Dermatol. 2014 May;150(5):535-41.

Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients.

Mignot G, Hervieu A, Vabres P, Dalac S, Jeudy G, Bel B, Apetoh L, Ghiringhelli F

PLoS One. 2014 Aug 29;9(8):e105907

Distinctive features of melanoma and its management in elderly patients: a population-based study in France.

Ciocan D, Barbe C, Aubin F, Granel-Brocard F, Lipsker D, Velten M, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Buemi A, Dalle S, Bernard P, Woronoff AS, Grange F

JAMA Dermatol. 2013 Oct;149(10):1150-7

Diagnosis and management of melanoma with regional lymph node metastases: a population-based study in France.

Levy-Sitbon C, Barbe C, Granel-Brocard F, Lipsker D, Aubin F, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Le Clainche A, Dalle S, Bernard P, Grange F

J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1081-7

Cheilitis, perioral dermatitis and contact allergy.

Collet E, Jeudy G, Dalac S

Eur J Dermatol. 2013 May-Jun;23(3):303-7

Clinical and sociodemographic characteristics associated with thick melanomas. A population-based, case-case study in France.

Grange F, Barbe C, Aubin F, Lipsker D, Granel-Brocard F, Velten M, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Buemi A, Dalle S, Bernard P, Woronoff AS

Arch Dermatol. 2012 Dec;148(12):1370-6.

The role of general practitioners in diagnosis of cutaneous melanoma: a population-based study in France.

Grange F, Barbe C, Mas L, Granel-Brocard F, Lipsker D, Aubin F, Velten M, Dalac S, Truchetet F, Michel C, Mitschler A, Arnoult G, Buemi A, Dalle S, Reuter G, Bernard P, Woronoff AS, Arnold F

Br J Dermatol. 2012 Dec;167(6):1351-9

Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases.

Vitte F, Fabiani B, Benet C, Dalac S, Balme B, Delattre C, Vergier B, Beylot-Barry M, Vignon-Pennamen D, Ortonne N, Algros MP, Carlotti A, Samaleire D, Frouin E, Levy A, Laroche L, Theate I, Monnien F, Mugneret F, Petrella T

Am J Surg Pathol. 2012 Sep;36(9):1302-16.

A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers.

Meaume S, Truchetet F, Cambazard F, Lok C, Debure C, Dalac S, Lazareth I, Sigal ML, Sauvadet A, Bohbot S, Dompmartin A

Wound Repair Regen. 2012 Jul-Aug;20(4):500-11

Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study.

Jouary T, Leyral C, Dreno B, Doussau A, Sassolas B, Beylot-Barry M, Renaud-Vilmer C, Guillot B, Bernard P, Lok C, Bedane C, Cambazard F, Misery L, Esteve E, Dalac S, Machet L, Grange F, Young P, Granel-Brocard F, Truchetet F, Vergier B, Delaunay MM, Grob JJ

Ann Oncol. 2012 Apr;23(4):1074-80

[Complications associated with sentinel lymph node biopsy for cutaneous melanoma. A retrospective study of 127 patients].

Duvernay A, Henault B, Danino MA, Trost O, Dalac S, Aubriot-Lorton MH, Zwetyenga N

Ann Chir Plast Esthet. 2012 Apr;57(2):151-7

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.

Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardiere A, Molinie V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugieres L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanche H, Zelenika D, Galan P, Aubin F, Bachollet B, Becuwe C, Berthet P, Bignon YJ, Bonadona V, Bonafe JL, Bonnet-Dupeyron MN, Cambazard F, Chevrant-Breton J, Coupier I, Dalac S, Demange L, d'Incan M, Dugast C, Faivre L, Vincent-Fetita L, Gauthier-Villars M, Gilbert B, Grange F, Grob JJ, Humbert P, Janin N, Joly P, Kerob D, Lasset C, Leroux D, Levang J, Limacher JM, Livideanu C, Longy M, Lortholary A, Stoppa-Lyonnet D, Mansard S, Mansuy L, Marrou K, Mateus C, Maugard C, Meyer N, Nogues C, Souteyrand P, Venat-Bouvet L, Zattara H, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B

Nature. 2011 Oct 19;480(7375):94-8

[Sentinel node procedure in head and neck cutaneous melanoma].

Roche M, Duvernay A, Dalac S, Malka G, Zwetyenga N, Trost O

Rev Stomatol Chir Maxillofac. 2011 Feb;112(1):6-10

[Management of cutaneous B-cell lymphoma: recommendations of the French cutaneous lymphoma study group].

Grange F, D'Incan M, Ortonne N, Dalac S, Laroche L, Beylot-Barry M, Delfau-Larue MH, Vergier B, Bagot M

Ann Dermatol Venereol. 2010 Aug-Sep;137(8-9):523-31

The Role of Circumstances of Diagnosis and Access to Dermatological Care in Early Diagnosis of Cutaneous Melanoma A Population-Based Study in France

Durbec F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hedelin G, Dalac S, Truchetet F, Michel C, Batard ML, Domissy-Baury B, Halna JM, Schmutz JL, Delvincourt C, Reuter G, Dalle S, Bernard P, Danzon A, Grange F

Arch Dermatol. 2010 Mar;146(3):240-6.

Management and outcome of metastatic melanoma during pregnancy.

Pages C, Robert C, Thomas L, Maubec E, Sassolas B, Granel-Brocard F, Chevreau C, De Raucourt S, Leccia MT, Fichet D, Khammari A, Boitier F, Stoebner PE, Dalac S, Celerier P, Aubin F, Viguier M

Br J Dermatol. 2010 Feb 1;162(2):274-81

Photosensitivity associated with selective serotonin reuptake inhibitors.

Doffoel-Hantz V, Boulitrop-Morvan C, Sparsa A, Bonnetblanc JM, Dalac S, Bedane C

Clin Exp Dermatol. 2009 Dec;34(8):e763-5

Fixed eruption due to quinine contained in tonic water: positive patch-testing.

Bel B, Jeudy G, Bouilly D, Dalac S, Vabres P, Collet E

Contact Dermatitis. 2009 Oct;61(4):242-4.

[Codification procedures for medical acts and diagnostic procedures in dermatology and allergology]

Collet E, Bismuth MJ, Dalac S

Ann Dermatol Venereol. 2009 Aug-Sep;136(8-9):668-73

Validation of a method to reduce the number of sentinel nodes removed in melanoma patients: a preliminary prospective survey.

Danino A, Malka G, Dalac S

Plast Reconstr Surg. 2008 Jul;122(1):43e-44e.

Variations in management of stage I to stage III cutaneous melanoma - A population-based study of clinical practices in France

Grange F, Vitry F, Granel-Brocard F, Lipsker D, Aubin F, Hedelin G, Dalac S, Truchetet F, Michel C, Batard ML, Baury B, Halna JM, Schmutz JL, Delvincourt C, Reuter G, Dalle S, Bernard P, Danzon A

Arch Dermatol. 2008 May;144(5):629-36.

[Study of variations between surgeons regarding inguinal lymph node clearance in melanoma]

Danino MA, Trost O, Malka G, Garrido I, Jebrane A, Dalac S

Ann Dermatol Venereol. 2008 Feb;135(2):142-4

Primary cutaneous diffuse large B-cell lymphoma, leg type - Clinicopathologic features and prognostic analysis in 60 cases

Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, Souteyrand P, Machet L, Dalac S, Esteve E, Templier I, Delaporte E, Avril MF, Robert C, Dalle S, Laroche L, Delaunay M, Joly P, Wechsler J, Petrella T

Arch Dermatol. 2007 Sep;143(9):1144-50.

Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standard, Options and Recommendations guidelines. Summary report

Saiag P, Bosquet L, Guillot B, Verola O, Avril MF, Bailly C, Cupissol D, Dalac S, Dreno B, Grob JJ, Leccia NT, Renaud-Vilmer C, Negrier S

Eur J Dermatol. 2007 Jul-Aug;17(4):325-31

Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.

Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, Collet E

J Allergy Clin Immunol. 2007 Mar;119(3):726-30

[Evaluation of a method to reduce the number of sentinel nodes removed in melanoma patients: prospective study]

Kadlub N, Trost O, Dalac S, Berriolo A, Ponelle T, Malka G, Danino A

Ann Chir Plast Esthet. 2007 Feb;52(1):24-7

Reducing the number of sentinel nodes removed in melanoma patients: a prospective study.

Danino AM, Kadlub N, Dalac S, Boichot C, Malka G

Indian J Cancer. 2006 Jul-Sep;43(3):132-5.

[Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report)].

Negrier S, Saiag P, Guillot B, Verola O, Avril MF, Bailly C, Cupissol D, Dalac S, Danino A, Dreno B, Grob JJ, Leccia MT, Renaud-Vilmer C, Bosquet L

Bull Cancer. 2006 Apr 1;93(4):371-84.

[Guidelines for clinical practice: Standards, Options and Recommendations 2005 for the management of adult patients exhibiting an M0 cutaneous melanoma, full report. National Federation of Cancer Campaign Centers. French Dermatology Society. Update of the

Negrier S, Saiag P, Guillot B, Verola O, Avril MF, Bailly C, Cupissol D, Dalac S, Danino A, Dreno B, Grob JJ, Leccia MT, Renaud-Vilmer C, Bosquet L

Ann Dermatol Venereol. 2005 Dec;132(12 Pt 2):10S3-10S85.

Clinical variants of the preprotuberant stage of dermatofibrosarcoma protuberans.

Martin L, Piette F, Blanc P, Mortier L, Avril MF, Delaunay MM, Dreno B, Granel F, Mantoux F, Aubin F, Sassolas B, Adamski H, Dalac S, Pauwels C, Dompmartin A, Lok C, Esteve E, Guillot B

Br J Dermatol. 2005 Nov;153(5):932-6.

[Is sentinel lymph node procedure in early-staged cutaneous melanoma really safe?]

Trost O, Danino AM, Dalac S, Herve C, Moutel G, Malka G

Ann Chir Plast Esthet. 2005 Apr;50(2):113-7

[What about sentinel node practice in early-staged cutaneous melanoma in France in 2003?]

Trost O, Danino AM, Kadlub N, Dalac S, Herve C, Malka G

Ann Chir Plast Esthet. 2005 Apr;50(2):99-103.

Positive sentinel nodes and melanoma of the head and neck.

Trost O, Danino AM, Malka G, Dalac S, Herve C

Plast Reconstr Surg. 2004 Oct;114(5):1348-9; author reply 1349-50.

Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas.

Grange F, Petrella T, Beylot-Barry M, Joly P, D'Incan M, Delaunay M, Machet L, Avril MF, Dalac S, Bernard P, Carlotti A, Esteve E, Vergier B, Dechelotte P, Cassagnau E, Courville P, Saiag P, Laroche L, Bagot M, Wechsler J

Blood. 2004 May 15;103(10):3662-8

Cutaneous malignant melanoma and neurofibromatosis type 1.

Guillot B, Dalac S, Delaunay M, Baccard M, Chevrant-Breton J, Dereure O, Machet L, Sassolas B, Zeller J, Bernard P, Bedane C, Wolkenstein P

Melanoma Res. 2004 Apr;14(2):159-63.

Dr DALAC Sophie

Fiche personne

coordonnées

Territoire

Statut

affiliation

Recherche

Publications